The convergence of advancing technology and the push for more effective, noninvasive cancer treatments is helping to build the perfect storm of innovation for the field of stereotactic radiosurgery. SRS allows high doses of precisely focused ablative energy to be delivered to targeted tissues with a minimum of damage to surrounding areas. It has been used for years to treat tumors in the head and neck, where patient movement can be effectively restrained with frames to protect healthy tissue. However, technological advances are now making the procedure more viable for tumors in other parts of the body, and that opens the door to treating cancers in the lung, prostate, breast, and beyond.
by Robert Neil
The convergence of advancing technology and the push for more effective, noninvasive cancer treatments is helping to build the perfect...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.
